TABLE 4.

Treatment and outcomes at 2 years post index biopsy

	Variables	cAMR (n = 49)	Control (n = 49)	P
Treatment for cAMR	Pulse steroid + IVIG, n (%)	28 (57%)	0
	Pulse steroid + IVIG + rituximabn (%)	21 (43%)	0
Maintenance immunosuppression 2–6 wk post-biopsy	Mean tacrolimus level (ng/mL)	6.56 ± 1.89	6.83 ± 1.72	0.50
	Mean mycophenolic acid dose (mg)	1297 ± 273	1236 ± 333	0.35
	Mean prednisone dose (mg)	12.3 ± 7.1	6.9 ± 2.25	<0.001
Kidney function at 2 y	eGFR (ml/min/1.73m2)	40.8 ± 14.3	51.7 ± 18.0	0.03
	SCr (mg/dl)	1.74 ± 0.69 (n = 20)	1.31 ± 0.55 (n = 42)	0.12
Outcome after 2 y	Total number of graft failure, n (%)	22 (45%)	3 (6%)	<0.001
	Death-censored graft failure, n (%)	16 (33%)	1 (2%)	<0.001

cAMR, chronic active antibody-mediated rejection; eGFR, estimated glomerular filtration rate; IVIG, intravenous immunoglobulin.